Pharvaris N.V. (PHVS) News
Filter PHVS News Items
PHVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PHVS News Highlights
- PHVS's 30 day story count now stands at 7.
- Over the past 5 days, the trend for PHVS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about PHVS are HAE, DEC and MET.
Latest PHVS News From Around the Web
Below are the latest news stories about PHARVARIS NV that investors may wish to consider to help them evaluate PHVS as an investment opportunity.
Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last weekKey Insights Significant control over Pharvaris by private equity firms implies that the general public has more power... |
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, B |
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study GoalData from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%. |
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study DataUpdates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week. |
AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ EventAdvanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today. |
Shopify (SHOP) Stock Falls Following Analyst DowngradeShopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt. |
Why Is Pharvaris (PHVS) Stock Up 36% Today?Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants. |
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded WarrantsZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”, Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, announced today the pricing of an underwritten offering of (i) 11,125,000 of its ordinary shares at a price of $24.00 per share and (ii) to one investor, pre-funded warrants to purchase 1,375,000 ordinary shares at a price of $23.99 per pre-funded warrant, which |
Pharvaris shares spike as drug appears to prevent symptoms of rare disorderThe company moved quickly to capitalize on the stock surge, announcing plans to raise $300 million through a secondary stock offering. |
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksPrimary endpoint met: deucrictibant significantly reduced attack rate The primary endpoint of the CHAPTER-1 study measured the time-normalized number of investigator-confirmed HAE attacks during the treatment period. The monthly attack rate was reduced by 84.5% (p=0.0008) compared to placebo in participants who received 40 mg/day of deucrictibant. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to place |